Press Release on the Financial Results of the Company for the quarter and year ended March 31, 2026
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories reported exceptional Q4FY26 results with total income surging 134.9% year-on-year to Rs. 788.7 crore. EBITDA jumped 448.6% to Rs. 319.4 crore with margins expanding dramatically from 17.3% to 40.5%. Profit after tax grew 666.3% to Rs. 212.5 crore versus Rs. 27.7 crore in Q4FY25. The company attributed performance to strong execution discipline, customer satisfaction, and business fundamentals. Management mentioned good short-to-medium term visibility anchored by commercial molecules, and ongoing investments in peptide manufacturing and a new R&D centre proceeding on schedule.
The stock should react very positively given the dramatic acceleration in revenue and profitability, along with significant margin expansion. The 666% PAT growth and 40%+ EBITDA margins signal strong operational leverage and could attract investor interest in the pharma API manufacturer.